BMC Research Notes | |
Association of serum vitamin B 12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study | |
Ahmad Amanzada2  Sabine Mihm2  Lars Reinhardt2  Armin D Goralzcyk1  Nicolae-Catalin Mechie2  | |
[1] Division of Internal Medicine, Clinic of Herzberg and Osterode, Dr Froessel Allee, Herzberg am Harz, 37412, Germany;Department of Gastroenterology and Endocrinology, University Medical Center Goettingen, Georg-August University Goettingen, Robert Koch Strasse 40, Göttingen, 37075, Germany | |
关键词: Sustained virological response; Vitamin B12; Genotype 1; Hepatitis C; | |
Others : 1231675 DOI : 10.1186/s13104-015-1248-z |
|
received in 2015-03-26, accepted in 2015-06-17, 发布年份 2015 | |
【 摘 要 】
Background
Chronic hepatitis C (CHC) is a global health challenge. New therapeutic agents with excellent sustained virological response (SVR) rates are available mainly in developed countries, while the majority of CHC patients live in countries with low health budget. Predictors of therapeutic response are therefore necessary. Vitamin B 12appears to be involved in hepatitis C virus replication.
Methods
We therefore studied retrospectively the relationship between baseline serum vitamin B 12levels and clinical features in 116 CHC genotype 1 infected patients. Logistic regression models with univariate and multivariate analysis were used in the statistical analysis.
Results
Baseline serum vitamin B 12levels were found to be positively associated with serum transaminase activities (AST, p = 0.002, ALT, p = 0.04), baseline viral load (p < 0.0001), stage of fibrosis (p = 0.0001) and favorable interferon-λ3/4 (IFNL3/IFNL4) rs12979860 genotypes (p = 0.04), and inversely with SVR (p < 0.001) as well as with rapid virological response (p = 0.001). Patients with baseline serum vitamin B 12levels below a cut-off value of 570 ng/L achieved a SVR rate of 59% with an odds ratio (OR) of 13.4 [confidence interval (CI) 4.3–41.9, p < 0.0001] compared to patients above the cut-off value. By combining serum vitamin B 12levels and IFNL3/IFNL4 rs12979860 genotypes, patients with baseline serum vitamin B 12levels below the cut-off value of 570 ng/L and IFNL3/IFNL4 rs12979860 CC genotype achieved a SVR rate of even 80% with an OR of 54 (CI 9.9–293, p < 0.0001) compared to patients above the cut-off value and non-CC-genotypes.
Conclusion
Our data suggest baseline serum vitamin B 12levels as useful noninvasive marker for characterizing CHC patients. They might further help to identify responders to a standard treatment.
【 授权许可】
2015 Mechie et al.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20151110081447162.pdf | 1035KB | download | |
Figure5. | 41KB | Image | download |
Figure4. | 24KB | Image | download |
Figure3. | 18KB | Image | download |
Figure2. | 16KB | Image | download |
Figure1. | 11KB | Image | download |
【 图 表 】
Figure1.
Figure2.
Figure3.
Figure4.
Figure5.
【 参考文献 】
- [1]Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, et al.: Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003, 98:2060-2063.
- [2]Global surveillance and control of hepatitis: C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium J Viral Hepat 1999, 6:35-47.
- [3]El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745-750.
- [4]Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al.: Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010, 28:3994-4005.
- [5]Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
- [6]Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
- [7]Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al.: Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009, 136:1618-1628.
- [8]Jensen DM, Marcellin P, Freilich B, Andreone P, Di BA, Brandao-Mello CE, et al.: Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009, 150:528-540.
- [9]Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al.: Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
- [10]Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al.: Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014, 383:515-523.
- [11]Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al.: Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014, 384:1756-1765.
- [12]Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al.: Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368:1867-1877.
- [13]Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al.: Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013, 381:2100-2107.
- [14]Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al.: Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221.
- [15]Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al.: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898.
- [16]Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al.: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-1493.
- [17]Petta S, Cabibbo G, Enea M, Macaluso FS, Plaia A, Bruno R, et al.: Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014, 59:1692-1705.
- [18]Asselah T, Estrabaud E, Bieche I, Lapalus M, De MS, Vidaud M, et al.: Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010, 30:1259-1269.
- [19]Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L: Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010, 105:1970-1977.
- [20]Ramcharran D, Wahed AS, Conjeevaram HS, Evans RW, Wang T, Belle SH, et al.: Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology 2010, 52:854-863.
- [21]Amanzada A, Goralczyk AD, Moriconi F, Van Thiel DH, Ramadori G, Mihm S: Vitamin D status and serum ferritin concentration in chronic hepatitis C virus type 1 infection. J Med Virol 2013, 85:1534-1541.
- [22]Amanzada A, Goralczyk AD, Schneider S, Moriconi F, Lindhorst A, Mihm S, et al.: High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and gamma-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study. Digestion 2012, 86:218-227.
- [23]Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, et al.: IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013, 210:1109-1116.
- [24]Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al.: A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013, 45:164-171.
- [25]Bartenschlager R, Lohmann V: Replication of the hepatitis C virus. Baillieres Best Pract Res Clin Gastroenterol 2000, 14:241-254.
- [26]Honda M, Brown EA, Lemon SM: Stability of a stem-loop involving the initiator AUG controls the efficiency of internal initiation of translation on hepatitis C virus RNA. RNA 1996, 2:955-968.
- [27]Takyar SS, Gowans EJ, Lott WB: Vitamin B 12 stalls the 80 S ribosomal complex on the hepatitis C internal ribosome entry site. J Mol Biol 2002, 319:1-8.
- [28]Lott WB, Takyar SS, Tuppen J, Crawford DH, Harrison M, Sloots TP, et al.: Vitamin B 12 and hepatitis C: molecular biology and human pathology. Proc Natl Acad Sci USA 2001, 98:4916-4921.
- [29]Rosenberg P, Hagen K: Serum B 12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection. J Viral Hepat 2011, 18:129-134.
- [30]Rocco A, Compare D, Coccoli P, Esposito C, Di SA, Barbato A, et al.: Vitamin B 12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut 2013, 62:766-773.
- [31]Mihm S, Fayyazi A, Hartmann H, Ramadori G: Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997, 25:735-739.
- [32]Ermens AA, Vlasveld LT, Lindemans J: Significance of elevated cobalamin (vitamin B 12 ) levels in blood. Clin Biochem 2003, 36:585-590.
- [33]Amanzada A, Schneider S, Moriconi F, Lindhorst A, Suermann T, van Thiel DH, et al.: Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. J Med Virol 2012, 84:1208-1216.
- [34]Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al.: Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014, 146:1669-1679.
- [35]Kau A, Vermehren J, Sarrazin C: Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-651.
- [36]Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
- [37]Kwo PY: Phase III results in Genotype 1 naive patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int 2012, 32(Suppl 1):39-43.
- [38]Mihm S, Monazahian M, Grethe S, Fechner C, Ramadori G, Thomssen R: Ratio of serum gamma-GT/ALT rather than ISDR variability is predictive for initial virological response to IFN-alpha in chronic HCV infection. J Med Virol 1999, 58:227-234.
- [39]Li D, Lott WB, Martyn J, Haqshenas G, Gowans EJ: Differential effects on the hepatitis C virus (HCV) internal ribosome entry site by vitamin B 12 and the HCV core protein. J Virol 2004, 78:12075-12081.
- [40]Joske RA: The vitamin B 12 content of human liver tissue obtained by aspiration biopsy. Gut 1963, 4:231-235.
- [41]Partearroyo T, Ubeda N, Montero A, Achon M, Varela-Moreiras G: Vitamin B(12) and folic acid imbalance modifies NK cytotoxicity, lymphocytes B and lymphoprolipheration in aged rats. Nutrients 2013, 5:4836-4848.